XML 40 R28.htm IDEA: XBRL DOCUMENT
v3.20.1

Note 21 - Research and Development Expenses | 12 Months Ended
--- | ---
Dec. 31, 2019
Notes to Financial Statements |
Research and Development Expenses [Text Block] | 21— RESEARCH AND DEVELOPMENT EXPENSES Research and development expenses consist of the following:
|  | 2019 |  | 2018 |  | 2017
Gross research and development expenses |  |  | (4,727 | ) |  |  | (4,863 | ) |  |  | (4,539 | )
Research Tax Credit |  |  | 762 |  |  |  | 685 |  |  |  | 504 |
Grants |  |  | 236 |  |  |  | 90 |  |  |  | 154 |
Net Research and development expenses |  |  | (3,728 | ) |  |  | (4,088 | ) |  |  | (3,881 | )
In 2019 grants consisted mainly of national grants for the assessment and optimization of the focal treatments of prostate cancer (Perfuse development project). In 2018 and 2017 grants mainly consisted of European, national and regional grants for the development of innovative imaging solutions for the focal treatment of liver cancer (HECAM Development project). Research and development costs are expensed as incurred and include amortization of assets, costs of prototypes, salaries, benefits and other headcount related costs, contract and other outside service fees, and facilities and overhead costs.

X
- Definition The entire disclosure for research and development expenses. + References No definition available. + Details
Name: | edap_ResearchAndDevelopmentExpensesTextBlock
Namespace Prefix: | edap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration